Subjects | 20 |
Age years | 67±9 (44–82) |
Female/male | 15/5 |
WHO-FC I/II/III/IV | 0/6/13/1 |
Patients previously treated with PEA | 1 |
Duration from onset of symptoms before BPA months | 60±63 (6–276) |
Previous PH-specific therapy# | 15 (75) |
Endothelin receptor antagonist | 6 |
Oral prostacyclin analogue | 13 |
Phosphodiesterase type-5 inhibitor | 4 |
Oral combination therapy | 6 |